JP2011522874A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522874A5
JP2011522874A5 JP2011513069A JP2011513069A JP2011522874A5 JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5 JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5
Authority
JP
Japan
Prior art keywords
influenza
virus
virus strain
vaccine
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011513069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522874A (ja
Filing date
Publication date
Priority claimed from GBGB0905570.8A external-priority patent/GB0905570D0/en
Application filed filed Critical
Publication of JP2011522874A publication Critical patent/JP2011522874A/ja
Publication of JP2011522874A5 publication Critical patent/JP2011522874A5/ja
Pending legal-status Critical Current

Links

JP2011513069A 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン Pending JP2011522874A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13191808P 2008-06-12 2008-06-12
US61/131,918 2008-06-12
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines
GB0905570.8 2009-03-31
PCT/IB2009/006038 WO2009150532A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection

Publications (2)

Publication Number Publication Date
JP2011522874A JP2011522874A (ja) 2011-08-04
JP2011522874A5 true JP2011522874A5 (enExample) 2012-07-19

Family

ID=40672059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513069A Pending JP2011522874A (ja) 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン

Country Status (9)

Country Link
US (2) US20110200635A1 (enExample)
EP (1) EP2303321A1 (enExample)
JP (1) JP2011522874A (enExample)
KR (1) KR20110019417A (enExample)
CN (1) CN102245203A (enExample)
AU (1) AU2009259006A1 (enExample)
CA (1) CA2727322A1 (enExample)
GB (1) GB0905570D0 (enExample)
WO (1) WO2009150532A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
DE102010018462A1 (de) * 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
US20120219584A1 (en) * 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
JP5884100B2 (ja) * 2011-08-31 2016-03-15 公益財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CN104159608A (zh) * 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
EP2931309A1 (en) 2012-12-17 2015-10-21 Eurocine Vaccines AB Intranasal vaccination dosage regimen
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105636609A (zh) * 2013-10-25 2016-06-01 白血球保健股份有限公司 一种新颖的生产稳定疫苗的方法
WO2016100926A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
WO2016104584A1 (ja) * 2014-12-25 2016-06-30 第一三共株式会社 皮内投与インフルエンザワクチン組成物
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019143955A1 (en) * 2018-01-22 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly protective inactivated influenza virus vaccine
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020219719A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN115003328A (zh) 2019-10-22 2022-09-02 西奈山伊坎医学院 重组神经氨酸酶及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
NZ594482A (en) * 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
AU2006310341B2 (en) * 2005-11-04 2011-01-06 Novartis Vaccines And Diagnostics Limited Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
CN101500603A (zh) * 2006-06-15 2009-08-05 诺华有限公司 节省佐剂的多剂量流感疫苗接种方案
NZ575271A (en) * 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) * 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
WO2008091657A1 (en) * 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良

Similar Documents

Publication Publication Date Title
Becker et al. Influenza vaccines: successes and continuing challenges
Vasou et al. Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses
Cargnin Faccin et al. Pandemic preparedness through vaccine development for avian influenza viruses
Cappellano et al. Nano-microparticle platforms in developing next-generation vaccines
Kumar et al. Novel platforms for the development of a universal influenza vaccine
Sekiya et al. Selecting and using the appropriate influenza vaccine for each individual
Vemula et al. Vaccine approaches conferring cross-protection against influenza viruses
Zhang et al. Universal influenza vaccines, a dream to be realized soon
Li et al. Adjuvantation of influenza vaccines to induce cross-protective immunity
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
JP6185548B2 (ja) インフルエンザワクチンの製造方法
Clegg et al. Clinical vaccine development for H5N1 influenza
ES2469568T3 (es) Vacuna contra la gripe
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Mokalla et al. Influenza vaccines: current status, adjuvant strategies, and efficacy
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
CN102548577A (zh) 用于抵抗流感的佐剂疫苗
Hsiung et al. Vaccine strategies against RNA viruses: current advances and future directions
Hatz et al. A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
Rudenko et al. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus
Chu et al. Respiratory viruses and virus-like particle vaccine development: how far have we advanced?
Tosh et al. Emerging vaccines for influenza
Esposito et al. Preventing influenza in younger children
Deans et al. Influenza vaccines provide diminished protection but are cost‐saving in older adults
EP2822585B1 (en) Improved vaccination against influenza